RxDoctor Payments Data

Brandon Workman, DO

Addiction Medicine · Beckley, WVNPI 1891012233

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Lundbeck LLC at 27.9% of the total. Reporting peaked in 2022 at $828 and has fallen 76.2% since, to $197 in 2025.

$2,600in general payments, 2019–2025

Across 147 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$726
  • Otsuka America Pharmaceutical, Inc.$706
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$317
  • Neurocrine Biosciences, Inc.$211
  • Avanir Pharmaceuticals, Inc.$141
  • Jazz Pharmaceuticals Inc.$123
  • plus $376 from 8 others

What the payments were for

  • Food & beverage$2,50196%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few addiction medicine providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$872
Medicare patients
76
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$104,157
NuedextaDextromethorphan Hbr/Quinidine19$22,739
VraylarCariprazine Hcl13$20,206
Aripiprazole234$16,625
Clozapine142$13,975
FetzimaLevomilnacipran Hcl20$11,879
TrintellixVortioxetine Hydrobromide15$9,832
BelsomraSuvorexant23$9,744
NamzaricMemantine Hcl/Donepezil Hcl16$7,190
Duloxetine Hcl383$4,970
VyvanseLisdexamfetamine Dimesylate14$4,863
Quetiapine Fumarate254$4,629
Ziprasidone Hcl46$4,491
Bupropion XlBupropion Hcl186$4,194
Buspirone Hcl185$3,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$211$104,15713 claims
Avanir Pharmaceuticals, Inc.Nuedexta$141$22,73919 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$22$14,69529 claims
Lilly USA, LLCOlanzapine$16$1,65769 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other addiction medicine in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →